Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

This study is testing a drug called crisugabalin for the treatment of generalized anxiety disorder (GAD) — a condition where people feel persistent, hard-to-control worry and anxiety about everyday situations. Researchers are evaluating the drug's safety and effectiveness in adults. **You may be eligible if...** - You are 18 or older (male or female) - You have been diagnosed with generalized anxiety disorder (GAD) according to DSM-5 criteria, confirmed with a structured clinical interview - You need medication to manage your anxiety symptoms - Your anxiety score (HAMA) is 20 or higher and your depression score is low - Your overall clinical impression of illness severity is at least moderate **You may NOT be eligible if...** - You have significant suicidal thoughts or have scored high on suicide risk assessments - You have significant depression alongside your anxiety (HAMD-17 score above 17) - Your anxiety scores dropped significantly during the screening period (may indicate a placebo response) - You have another psychiatric condition such as bipolar disorder, OCD, psychotic disorder, or severe personality disorder - You have a history of depression, obsessive-compulsive disorder, or somatoform disorder Talk to your doctor to see if this trial is right for you.